The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.
21h
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...
If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable ...
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback